In biomedical imaging, nanoparticles combined with radionuclides that generate Cerenkov luminescence are used in diagnostic imaging, photon-induced therapies and as activatable probes. In these applications, the nanoparticle is often viewed as a carrier inert to ionizing radiation from the radionuclide. However, certain phenomena such as enhanced nanoparticle luminescence and generation of reactive oxygen species cannot be completely explained by Cerenkov luminescence interactions with nanoparticles. Herein, we report methods to examine the mechanisms of nanoparticle excitation by radionuclides, including interactions with Cerenkov luminescence, β particles and γ radiation. We demonstrate that β -scintillation contributes appreciably to excitation and reactivity in certain nanoparticle systems, and that excitation by radionuclides of nanoparticles composed of large atomic number atoms generates X-rays, enabling multiplexed imaging through single photon emission computed tomography. These findings demonstrate practical optical imaging and therapy using radionuclides with emission energies below the Cerenkov threshold, thereby expanding the list of applicable radionuclides.
I onizing radiation sources such as linear accelerators and more commonly radionuclides are often combined with nanoparticles (NPs) for medical applications 1-5 . Radiolabelled NPs have found use in clinical 6, 7 and preclinical sentinel lymph node imaging 4, 8 , long-term NP integrity studies 9 and tumour imaging through active targeting and the enhanced permeability and retention (EPR) mechanisms 10, 11 . While radiolabelled NPs have been typically detected using single photon emission computed tomography (SPECT) or positron emission tomography (PET) 12 there is increasing interest in utilizing Cerenkov luminescence (CL) 13, 14 . CL is the visible blueweighted light that emanates when a charged particle, such as a β particle, travels faster than the phase velocity of light in a particular medium. Since first shown in preclinical in vivo systems in 2009 15 , Cerenkov luminescence imaging (CLI) is being rapidly translated to the clinic [16] [17] [18] [19] [20] [21] .
Imaging and therapeutic applications using ionizing radiation combined with NPs have generally neglected direct interactions between the ionizing radiation and the NP. Research has focused on CL generated in the medium interacting with fluorescent NPs such as quantum dots for secondary Cerenkov-induced fluorescence imaging (SCIFI) 22 . CL research has extended into TiO 2 NP-based photodynamic therapy (PDT) with both radionuclides 3 and external beams 23 . These studies explained the mechanism of PDT as CL from the ionizing radiation source exciting the NP-based PDT agent, generating reactive oxygen species. However, the very low CL photon fluence predicted from radionuclides (nJ cm −2 ) compared to external beam radiation (mJ cm −2 ) 24 strongly suggests that additional NP excitation mechanisms are necessary for therapy.
Ionizing radiation results in the excitation and ionization of the surrounding medium, in this case the NP, as energy is dissipated to reach thermal equilibrium 25 . One mechanism by which NPs can relax to the ground state is through radiative processes, such as scintillation. Gamma-scintillation (photon production from γ -emitters) has been studied in quantum dots 26 and rare-earth NPs [27] [28] [29] [30] [31] (Fig. 1a ). The contribution of β energy on NP systems has been neglected as β + (that is, positron) radionuclides in biomedical imaging (such as 18 F and 68 Ga) also ultimately emit γ photons from positron annihilation in addition to CL. Common β − (that is, electron) emitting radionuclides such as 90 Y and 32 P also emit CL, thereby obscuring the contribution from each mechanism. Previous studies relied on physical shielding to block specific types of interactions (CL, γ , β ) between a source and target. This approach led to the conclusion that Eu 2 O 3 NPs were not excited by β interactions from the 18 F positron 27 . However, due to the short positron range of 18 F in water 32 (β avg = 0.25 mm, β max = 2.0 mm) most positrons were annihilated prior to interacting with the NPs, limiting the possible interactions.
Here, we report new assays using radionuclides that do not emit CL to determine β and γ interactions with NPs. We demonstrate that β interactions significantly contribute to excitation of widely used nanoparticles such as Eu 2 O 3 and TiO 2 , investigated for imaging 27 and therapy 3 , respectively. We furthermore demonstrate that ionizing radiation in the presence of NPs containing high-atomicnumber (Z) elements results in emission of characteristic X-rays in the 1-100 keV range. These X-rays allow for a new strategy in biomedical imaging using a SPECT scanner for multiplexed, NP-specific in vivo imaging. Our investigation into the various interactions between ionizing radiation with NPs better explains previous imaging and photodynamic therapy results in addition to a new imaging paradigm.
Visible photon output from radionuclide-NP pairings
Because clinical radionuclides decay through multiple high-energy emissions (Table 1) , we first aimed to delineate NP excitation Nanoparticles as multimodal photon transducers of ionizing radiation Edwin C. Pratt 1,8 , Travis M. Shaffer 2,3,4,5,6,8 , Qize Zhang 3,4,5 , Charles Michael Drain 4,5 and Jan Grimm 1,2,3,7 * mechanisms that result in output of visible light. Radionuclides that emit only β − or γ were selected as excitation sources and added to a library of NPs that are of interest for biomedical imaging (Table 2) , including amorphous silica NP (SNP), TiO 2 , HfO 2 , Eu 2 O 3 , Gd 2 O 3 and YAG:Ce (cerium-doped yttrium aluminium garnet). The pure excitation sources were combined directly with either the NP suspension or an H 2 O control solution. The pure β − emitters 35 S and 3 H were used since the maximum energies (β max ) are below the CL threshold in water. The γ emitter 99m Tc was used to assess contributions from γ excitation. Although 99m Tc and 35 S do not result in CL, ionization and excitation of H 2 O (ref. 33 ) can produce photons but are several orders weaker than CL.
When 30 μ Ci of 3 H, the lowest energy pure β − emitter, were combined with the NP panel, radiance enhancements over 3 H in H 2 O were observed: SNP (1.2-fold), TiO 2 (55-fold), HfO 2 (4-fold), Eu 2 O 3 (179-fold), Gd 2 O 3 (301-fold) and YAG:Ce (376-fold) ( Fig. 2a ). Because the short trajectory of the low-energy β emitted for 3 H may only interact with a few NPs, we next tested the radiance enhancements with more-energetic radionuclides. 35 S yielded greater photon flux enhancements for NP combinations: SNP (1.3-fold), anatase TiO 2 (20-fold), HfO 2 (29-fold), Eu 2 O 3 (715-fold), Gd 2 O 3 (1,417-fold) and YAG:Ce (357-fold). The addition of 99m Tc, a pure γ -emitter, to NPs in the panel yielded similar enhancements: anatase TiO 2 (234-fold), HfO 2 (230-fold), Eu 2 O 3 (675-fold), Gd 2 O 3 (2,406fold) and YAG:Ce (1,174-fold). Thus, both β -and γ -emitting radionuclides combined with NPs led to scintillation and appreciable increases in radiance. Importantly, the radiances from Eu 2 O 3 , Gd 2 O 3 and YAG:Ce were approximately fourfold greater with 35 S (β ) compared to 99m Tc (γ ) demonstrating that, contrary to previous reports 27 , β -scintillation is a crucial mechanism in NP excitation ( Fig. 2b) . Furthermore, the enhancement of NP radiances is dependent on the amount of radioactivity present, ( Supplementary Fig. 1 ). Both activity titrations and tissue attenuation studies were conducted to confirm linearity ( Supplementary Fig. 2 ). Although both β and γ radionuclides were shown to excite NPs without involving CL, it remained to be determined if one type of excitation would dominate or if they are additive. Therefore, 35 S and 99m Tc were added sequentially to each NP well in both orders (β then γ radionuclide and vice versa). The addition of the second radionuclide yielded additive radiances thus the order of addition did not significantly matter ( Fig. 2c ). To assess the radiance dependence on the NP structure rather than the metal ion, an equimolar solution of europium cations was tested with 100 μ Ci 35 S and found to yield only 13% of the radiance of Eu 2 O 3 NP containing the same amount of Eu ( Fig. 2d ). Radiances observed from pure β − -emitting and γ -emitting radionuclides with NPs ( Fig. 2a,b ) are summarized and plotted in Fig. 2e (standard deviation shown alone in Supplementary Fig. 3 ). The effect of NP size on enhancement was also determined by using three sizes of Eu 2 O 3 NPs normalized to particle number, volume or surface area. When mixed with 18 F-FDG, the enhancement for the different sized Eu 2 O 3 NPs varied less than threefold ( Fig. 2f ) while each is nearly 100-fold brighter than 18 F-FDG alone, suggesting the enhancement is more dependent on the molar amount of europium within NPs and less dependent on particle size in the range tested. While certain NPs are more luminescent than others, the addition of sub-CL energy radionuclides results in increased luminescence of up to nearly 2,500 times that of the radionuclide alone ( 35 S with Eu 2 O 3 NPs) and distinct from chemiluminescence ( Supplementary Fig. 4 ). To determine overall changes in the photon flux due to NP interactions, clinically used radionuclides from Table 1 were next explored with NPs in Table 2 . Clinical β -emitting isotopes emit CL in water according to the Frank-Tamm (equation (1)) showing that CL increases with particle energy ( Fig. 2g ) and the refractive index of the medium. The clinical isotopes 18 F, 68 Ga, 177 Lu and 90 Y isotopes with high-energy emission were used to observe total radiance enhancements by NPs. Radiance enhancement for high-energy electron and γ -emitting 90 Y and 177 Lu and 511 keV γ -emitting 18 F, 68 Ga and 89 Zr were measured ( Fig. 2h ). Similar results to 90 Y were observed with the addition of the pure high-energy β emitter 32 P ( Supplementary Fig. 5 ). The 511 keV γ from positron annihilation was also tested with the NPs from Table 2 , and were not found to produce radiances as large as direct addition of 99m Tc (Supplementary Figs. 6 and 21), in agreement with previous results 27 .
The Frank-Tamm formula defines photon output over a distance (dN/dx), where α is the fine structure constant, β is the velocity of the particle relative to the speed of light in a vacuum, n is the refractive index of the medium, and λ is the wavelength of interest in the ultraviolet-visible region.
Of the NPs tested, Eu 2 O 3 and Gd 2 O 3 exhibited the largest enhancement in radiance. Enhancements using 177 Lu, 18 
Characteristics of NP photon generation
To further understand the optical output of the NP radionuclide combinations, spectra for each of the NPs with β and γ -emitting radionuclides were measured from 250-840 nm in a plate reader ( Fig. 3a ) and in smaller but discrete step values from 500-840 nm on an IVIS optical imaging system (Fig. 3b ). Disregarding material specific absorption, pure CL has the characteristic 1/λ 2 wavelength intensity profile ( Supplementary Fig. 10 ), whereas discrete ionizations and excitations would exhibit known atomic transitions for scintillation or NP photoluminescence. The combination of Gd 2 O 3 and Eu 2 O 3 with 68 Ga and 18 F, respectively, produced distinct visible emission peaks ( Fig. 3a,b ) using a 540 nm narrow band emission filter 35 for Gd 3+ , and characteristic f-f transitions for Eu 3+ using 620 and 700 nm filters 36 . The less luminescent NPs such as HfO 2 , TiO 2 , Bi 2 O 3 and YAG:Ce produced weaker and broader emission peaks in the 400-840 nm window ( Fig. 3a , Supplementary Fig. 10 ). The emission peak for HfO 2 at 495 nm could not be resolved with the factory installed filters 37 but is visible on the well plate scan ( Fig. 3a ). YAG:Ce has a photoluminescence peak at 540-560 nm (ref. 38 ) but is weak compared to Gd 2 O 3 and Eu 2 O 3 . No differences were observed between traditional laser excitation and emission spectra of these particles compared to spectra collected with radionuclides ( Supplementary Fig. 11 ). Spectral peaks were identical on the IVIS when excited by α emitters 225 Ac or 223 Ra ( Supplementary Fig. 12 ).
The f-f transitions appear with both β and γ radionuclides, suggesting both as sources for scintillation with Eu 2 O 3 , Gd 2 O 3 and YAG:Ce.
The signature emission peaks were retained in vivo ( Supplementary Fig. 14) , where Matrigel phantoms ( Fig. 3c -e) showed nearly fivefold enhanced radiance with Eu 2 O 3 compared to 32 P alone using the open filter ( Fig. 3d ). Using a 620 nm filter, only the emission from Eu 2 O 3 phantom in the presence of activity was visible ( Fig. 3e ). A significant advantage is that the red photons from the europium emission spectrum are much less attenuated in vivo than the blue weighted light from CL 13 . β nuclides such as 32 P can be used to produce selective optical emission both in vitro ( Fig.  3b ) and in vivo ( Fig. 3e-j) . Similarly, a comparison of Eu 2 O 3 and Gd 2 O 3 Matrigel plugs with 32 P in vivo ( Fig. 3f-j) show the emission for Gd 3+ using the 540 nm filter (Fig. 3h ), and for both particles at longer wavelengths using 620 nm and 700 nm filters, respectively ( Fig. 3i-j ).
NP-multiplexed SPECT imaging
β particles can interact with matter via mechanisms that include CL, electron excitation, ionization, bremsstrahlung and annihilation (β + only), while γ particles can interact with matter through the photoelectric or Compton effects, coherent scattering or pair production ( Supplementary Fig. 9 ). During ionization, characteristic X-rays are generated through an L shell electron occupying the vacancy of a previously ejected K shell electron. As the ejected X-ray represents a specific energy loss from an element, these X-rays are commonly used to determine elemental composition of materials based upon X-ray fluorescence (XRF) 39, 40 . Therefore, the NP panel was combined with β -or γ -emitting radionuclides, and evaluated for X-rays originating from the various NPs below 100 keV. Each of the β − radionuclides tested (except 3 H, which has energy emissions too low to eject K shell electrons) showed a broad bremsstrahlung emission profile as expected in addition to characteristic X-rays, denoted Kα and Kβ , that were dependent on the NP composition. Figure 4a presents the typical X-ray spectra for each of the NPs from the pure β − emitter 32 P on top of a background of bremsstrahlung. Characteristic X-ray peaks were observed for Ge, YAG:Ce, Eu 2 O 3 , Gd 2 O 3 , HfO 2 , Au and Bi 2 O 3 , while no X-ray peaks were observed for glucose, silica and anatase TiO 2 . Characteristic X-ray production rates increase with both energy of the β radionuclide and atomic number 41 , explaining the lack of observed characteristic X-ray peaks for lower-Z materials like silica, TiO 2 and glucose. Here, we observe that in addition to scintillation occurring to produce visible light (Figs. 2 and 3), NPs are ionized producing characteristic X-rays in addition to bremsstrahlung by β − -emitting nuclides. The ionization peaks were identical using 99m Tc (Fig. 4b ).
The efficiency of X-ray peak generation by the radionuclides was not calculated; however, an overlay of α -, β + -, γ -and β − -emitting nuclides tested with Eu 2 O 3 all show the formation of characteristic X-rays ( Supplementary Fig. 15 ).
While rare earth NPs have been excited in vivo using exogenous X-ray beams to produce photons 30, 42 , X-rays emitted from the NP by ionization from endogenous radionuclides can be used for multicolour NP specific imaging. With an adjustable keV photon energy window, a SPECT instrument represents an ideal imaging platform for this modality. For NP composed of higher-Z atoms like europium, gadolinium, gold and bismuth, the characteristic keV photons generated from ionization enables direct detection by X-ray imaging, and the different X-ray energy emitted (Table 2) enables multimodal detection. A titration curve was produced for Eu 2 O 3 using 35 S, 32 P and 99m Tc, where 99m Tc showed the greatest signal of europium X-rays per unit of activity ( Fig. 4c ) and demonstrated that imaging on a preclinical platform was both feasible and quantitative ( Supplementary Fig. 16 ). To test the multicolour capability of this system, a well plate was prepared containing either Eu 2 O 3 , HfO 2 , or Bi 2 O 3 with 99m Tc and X-ray emissions were detected at the energies corresponding to the predominant metal in each particle (Fig. 3d ). The top panel in Fig. 3d shows the 140 keV photopeak from 99m Tc activity, while the subsequent panels show X-ray emission for europium, hafnium and bismuth. A corresponding study was also done using mixtures of these NP ( Supplementary Fig. 17 ) demonstrating that X-rays from mixtures can be resolved with an X-ray signal dependent on the composition of the mixture. To test the multiplexing in vivo with a pure β − emitter, Matrigel plugs containing Eu 2 O 3 or Bi 2 O 3 NPs were implanted into a nude mouse with or without 32 P ( Fig. 4e-g) . The Matrigel phantom containing both 32 P and the Eu 2 O 3 show a distinct signal for europium that is not seen in any other phantom (Fig. 4f) . Similarly, the phantom containing Bi 2 O 3 and 32 P shows the highest intensity for bismuth characteristic X-rays ( Fig. 4g) and is specific to the detection channel used ( Supplementary Fig. 18 ) provided the detector can resolve the X-ray energy difference.
Clinical relevance and new imaging technology
Beyond SiO 2 , TiO 2 and AuNP, most NPs investigated face a large barrier for clinical translation. In particular, there is known toxicity for uncoated rare earth oxides in lysosomes 43 . Rare earth NP toxicity must be mitigated by increasing surface biocompatibility and facilitating biological clearance. However, our results highlight that NPs in proximity to clinical radionuclides provide enhanced photon radiance and generate characteristic X-rays that can be used in several modes of imaging. The high energy of 90 Y makes this new SPECT mode of imaging immediately clinically relevant with Theraspheres or other 90 Y sources. Theraspheres are glass microspheres containing 90 Y and are Food and Drug Administration approved for radioembolization of primary liver tumours when delivered by catheter directly to the tumour via the hepatic artery branches. Imaging their location in vivo has proved challenging. Therefore, we assessed our imaging technique on the combination of Theraspheres and bismuth or europium NPs. This is advantageous over, for example, mixing the spheres with small molecule radiotracers that could quickly dissipate from the injection site (for example, 99m Tc-Methyl diphosphonate). Tumour bearing mice received intratumoural injections of Theraspheres or Theraspheres co-injected with either bismuth or europium NPs. In the europium and bismuth energy windows (~10 keV width total), Theraspheres Fig. 4 | high-energy spectra and imaging of NP ionization from radionuclides. a, Characteristic X-ray spectra with the pure β − emitter 32 P showing qualitative abundance and increasing Kα and Kβ energy with increasing atomic number (Z) from 1-100 keV. × 10 magnification above YAG:Ce trace represents characteristic X-rays of the cerium dopant upon longer measurement (representative spectra shown). b, Identical characteristic X-rays generated using 99m Tc from 1-100 keV. For Eu 2 O 3 , characteristic X-ray peaks were produced using clinical radionuclides 90 Y, 68 Ga, 18 F and 177 Lu ( Supplementary Fig. 15 ). c, X-ray generation curves from 99m Tc, 32 alone showed no appreciable signal in either X-ray channel (Fig. 5a,b ) compared to Theraspheres co-injected with Eu 2 O 3 or Bi 2 O 3 NPs (Fig. 5c,d) . A modest CT contrast was observed with Theraspheres, and enhanced with either europium or bismuth NPs ( Supplementary Fig. 19 ) for visual location recognition. Here, select high-Z NPs served as an imaging agent for Therasphere detection by SPECT, opening up the possibility for multimodal detection with other NP agents simultaneously.
Next, the same technique was used to visualize lymphatic drainage and identify sentinel, locoregional draining lymph nodes, a procedure critical in oncologic surgery 8 . Eu 2 O 3 NPs coated with silica and PEGylated AuNPs were synthesized to visualize drainage using chelator free 4 and chelate methods with 90 Y respectively. NPs were injected into either hind footpad to monitor lymph node drainage by IVIS (Fig. 5e ). The smaller AuNPs (80 nm versus 240 nm) drained nearly fifteen times faster ( > 30 μ m s -1 ) and reached the sentinel and higher echelon nodal stations faster as compared to the larger Eu 2 O 3 NPs. This method would allow analysing lymphatic functionality preclinically. Furthermore, 620 nm and 700 nm emission windows enabled selective imaging of Eu 2 O 3 only drainage ( Fig. 5f ). Sentinel lymph node drainage of AuNPs was also seen using the X-ray energy window for gold ( Fig. 5g, Supplementary  Fig. 20) . While other means of detecting sentinel nodes exist, there are no clinical approved means to determine lymphatic function both non-invasively with SPECT for pre-surgical mapping and optically during surgery using the same agent and thus imaging the same biodistribution. Further miniaturization and targeting could allow this system to move beyond lymph node drainage to image specifically tumour distribution for preclinical mapping and intraoperative imaging. Supplementary Fig. 20 . h, Non-CL light based PDT. Radionuclides 18 F, 35 S and 99m Tc were added to cells in vitro, along with TiO 2 NP with transferrin attached (Tf) with and without titanocene (Tc). Therapeutic effects were demonstrated with radionuclides that do not emit CL, highlighting NP derived light can be as useful for PDT alongside CL (n = 3 independent samples; centre value, mean; error bars, s.d.). **P < 0.01; ****P < 0.0001; ns, not significant. Colour bars in a-d,g are maximum intensity projections, with dark blue representing minimum intensity and yellow representing maximum instensity, and scale bars are quantified with number of counts measured (a.u.).
Combining TiO 2 with sub CL radionuclides produced appreciable photon flux enhancements. Therefore, based on the photodynamic therapy previously described 3 through CL, we sought to evaluate and compare the therapeutic effect in vitro of sub-CL radionuclides together with TiO 2 transferrin (Tf) and titanocene (Tc) NPs. The radionuclides 18 F, 35 S and 99m Tc were chosen to test if CL alone, or NP-derived visible light from β -or γ -scintillation, are sufficient to elicit a therapeutic effect. No significant difference in viability was seen between radionuclide and the addition of TiO 2 Tf for all three radionuclides tested; however, the addition of TiO 2 TfTc produced a significant therapeutic effect (Fig. 5h) . By using the non-CL radionuclides 35 S and 99m Tc, we demonstrate each aforementioned mechanism (not just CL) can be a contributor to a PDT effect from radiotracers and TiO 2 , as hypothesized previously.
Conclusions
Radionuclide-NP combinations are widely used in vivo because of the high specific activity, payload and multifunctional properties achievable with NPs. The types of interactions between ionizing radiation and NP that produce photons are dependent on both the NP's and the radiotracer's physical characteristics, summarized in Fig. 6 . Low-energy radionuclides such as 3 H can polarize regions on a NP while higher energy β emitters can produce CL in a NP but can also ionize, causing characteristic X-ray production. Gammaemitting radionuclides operate through the photoelectric effect where an incident gamma ray is deposited into electrons that could recombine or relax to generate light. Gamma radiation can also generate characteristic X-rays if a K-shell electron is ionized. Clinical radionuclides can produce several high-energy β and γ emissions, each producing light through the aforementioned mechanisms on a given NP.
The visible light emanating from β -emitting radiotracers has allowed preclinical and clinical luminescence imaging through CL 16 , but the photon flux is quite low. NPs in proximity to either β or γ -emitting radionuclides were shown to exhibit enhanced total photon flux and to emit at discrete wavelengths in systems with luminescent metal ions. Exploring the mechanisms of NP radiance with radionuclides that emit only a single type of radiation revealed unforeseen contributions of NP luminescence from the β particle. Our study sets the stage for imaging with all β -emitting radionuclides, exploiting the advantages of an enhanced signal emanating from the NP compared to CL alone. Using radionuclides with radiosensitizing agents for photodynamic therapy is increasingly investigated [44] [45] [46] , and a greater understanding of how NPs can increase photon density for PDT should aid progress. Additionally, the heretofore unappreciated characteristic X-rays resulting from these interactions yields a new imaging modality in SPECT. These findings have broad implications for nuclear detection, optical imaging and design of high-Z NPs for imaging and therapy. Beyond the biosciences, these results can be exploited in environmental and material analytics.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41565-018-0086-2. 
Nanoparticle preparation. All NPs except SiO 2 and AuNP were purchased from either American Elements or Sigma Aldrich. SiO 2 NPs were prepared via a modified Stöber method 4 . Silicated Eu 2 O 3 NPs were prepared based on a modified gold NP method described previously 48 . Nanopowders were suspended in an aqueous solution of 60% by weight glucose with the aid of a 500 W tip sonicator to create a NP suspension. Au-PEG-DOTA NPs were prepared using an established AuNP protocol followed by thiol-PEG-NHS coupling (Nanocs, HS-PEG10k-NHS) and immediate conjugation with S-2-(4-Aminobenzyl)-1,4,7,10-tetraazacyclododecane tetraacetic acid (macrocyclics) under slightly basic conditions. Particles were purified and concentrated by tangential flow filtration using a Spectrum hollow fibre MicroKros 50 kD mPES membrane and stored at 4 °C until chelation with 90 Y at 37 °C in 200 mM acetate buffer pH 5.5.
Nanoparticle characterization. NP morphology and diameter were determined using both a Jeol 200 kV TEM and a Malvern Zetasizer Nano ZS. A Malvern Nanosight NS500 instrument was used to determine particle concentration. The absorbance and photo-luminescence was determined on a SpectraMax M5 plate reader via quartz cuvette using 1 × 10 10 particles per ml or lower and extrapolated when an optical density of 1 was exceeded. Excitation and emission spectra were acquired on a Cary Eclipse Fluorescence Spectrometer and the SpectraMax M5 plate reader at 1 mg per ml.
Radiotracer production. Hydrogen-3, phosphorus-32, sulfur-35, lutetium-177 and yttrium-90 were purchased from PerkinElmer as liquid solutions. When appropriate, solutions were brought to neutral pH prior to addition to NP solutions. Zirconium-89 was produced on the MSK cyclotron and purified as zirconium oxalate. This was neutralized with sodium carbonate prior to use. Gallium-68 was produced on a germanium generator and eluted in 0.3 N HCl. This was neutralized with 28% ammonium hydroxide prior to use. Fluorine-18 was obtained from the MSK nuclear pharmacy in the form of 18 Beta, gamma and X-ray interactions for visible light modulation. 24 well black walled plates from Greiner were used for IVIS optical imaging. NP solutions were prepared as previously stated at 1 × 10 10 , 1 × 10 11 and 1 × 10 12 particles per ml. 1 ml of nanosuspension was diluted with 5 μ l of the radionuclide of interest, targeting 30 μ Ci (1.11 MBq) per well at time of measurement. Imaging was performed on an IVIS Spectrum at f = 1 for durations of 60 s to 300 s with an open filter. Initially the NPs in the panel (Table 2) were measured without any radioactivity to determine background radiative output. Spectrum scans were acquired using 20 nm increment filters between 500 nm and 840 nm on the IVIS Spectrum or between 250-840 nm in 10 nm increments on the SpectraMax M5. For the IVIS Spectrum, regions of interest (ROIs) were drawn over each well and radiance values were reported in p s -1 cm -2 sr -1 after background subtraction averaging n = 3 wells and decay correction. Enhancement was normalized to the radiance of an identical activity of radionuclide in H 2 O. Well plate IVIS experiments were done in triplicate with spectral measurements done over the course of three hours per plate. Plates were replicated on subsequent weeks with at least n = 3 replicate experiments for a nanoparticle radionuclide combination. Radionuclide radiances alone were determined on the IVIS using a minimum of four replicates per activity level per nuclide with at least five different activity amounts. Radiances were then normalized to the intensity per unit of activity per volume.
High-energy photon luminescence measurements. Supplementary Fig. 22 for set-up diagram.
X-ray and gamma ray spectroscopy. Measurement of the X-ray and gamma spectrum between 1 and 1,700 keV was performed on a Canberra broad energy Ge detector. 1 × 10 12 particles in an Eppendorf tube were placed at a fixed height in the detector, and activity was added such that crystal dead time was between 1-5% for γ and pure β emitters. Clinical isotopes were added at similar activities, resulting in ~60% dead time due to additional counts from emitted gammas. Spectra were qualitatively compared to blank tubes containing identical amounts of activity in 60% glucose only. Channel peaks were calibrated to energies with the use of an 241 Am 1.0 μ Ci source found in a Family Gard FG200 smoke detector. Spectra peaks were compared to atomic transitions of the NP elements using the NIST X-ray Transitions Database 49 .
Modified SPECT-CT imaging using characteristic X-rays. 0.5-1 mCi (18.5-37 MBq) of 32 P was mixed with nanoparticles (1 × 10 11 NPs) and Matrigel and subcutaneously injected into athymic nude mice for pilot phantom studies. AuNP tail drainage experiments were done using 270 µ Ci (9.9 MBq) of 90 Y chelated to ~10 mg of AuNPs and injected intradermally into the tail of an athymic nude mouse. Energy windows for imaging were selected based upon main Kα and Kβ transitions on a Mediso nanoSPECT/CT ( Supplementary Fig. 23 ). We constructed artificial isotopes in the Mediso isotope master file and subsequently performed energy and uniformity calibrations to prepare the nanoSPECT/CT for NP characteristic X-ray imaging. SPECT images were acquired using the standard high-energy pinhole collimators, a scan time of 1 h, and with 35-60% smoothing for acquired SPECT images.
In vivo imaging with athymic nude mice. Animal experiments were done in accordance with protocols approved by the Institutional Animal Care and Use Committee of Memorial Sloan Kettering Cancer Center and followed National Institutes of Health guidelines for animal care. Athymic male nude mice were used for lymph node drainage studies while athymic female nude mice were implanted orthotopically with BT-474 cells and injected intratumourally with 1 mCi of 90 Y Theraspheres with and without 1 × 10 11 Eu 2 O 3 or Bi 2 O 3 NPs. Cells were authenticated but not checked for mycoplasma while in culture. Europium oxide nanoparticles were silicated and annealed in a 500 °C oven for 1 h before chelatorfree radiolabelling with 90 Y. Approximately 270 µ Ci (9.9 MBq) of 90 Y labelled NPs (10 mg AuNP or 5 mg Eu 2 O 3 ) were injected into either hind food pad and imaged on the IVIS every 15 min through 3 h and then subsequently at 6 and 12 h.
In vitro PDT using TiO 2 NPs. Experimental conditions were based on methods described previously for TiO 2 NPs 3 . TiO 2 NPs from Sigma were washed with Chelex grade water and dispersed in 1 × DPBS at a concentration of 1 mg ml -1 . Apo-transferrin from Sigma was dissolved in 1 × DPBS at a concentration of 10 mg ml -1 and diluted 1:1 with TiO 2 NP dispersion. TiO 2 Tf dispersion was placed on a cold block and tip sonicated for 120 s with a 5 s on, 10 s off pulse sequence. Dispersion was immediately filtered with 0.45 µ m filter and measured for NP absorbance relative to a known unfiltered sample. Titanocene was dissolved in DMSO and added to the TiO 2 Tf NPs before incubation with HT1080 fibrosarcoma cells overnight. Cells were authenticated but not checked for mycoplasma while in culture. Radionuclides were added the following day at concentrations between 0.01-0.80 mCi per well (n = 3 per condition). Plates were placed in a shielded incubator for 72 h before MTS viability assay. The MTS assay was read out using an M5 spectramax plate reader. 
Statistical analysis. Graphpad

Data exclusions
Describe any data exclusions. Data sets excluded were done so based upon poor mixing and high SD of the triplicate wells. nanoparticles that were high light absorbers (like Ge) were removed from main figures to simplify results. SPECT scans excluded were done based upon image acquisition and processing faults (wrong energy calibration or wrong energy map).
Replication
Describe whether the experimental findings were reliably reproduced.
Well plate experiments were done in triplicate and have been repeated at least two times. preparation of nanoparticle solutions was standardized to a concentration (1e12/mL) and made fresh before measurements.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Well plate studies were not randomized, but controlled where each plate image acquired contained the nanoparticles without any radionuclide, the radionuclide alone, and the select nanoparticles with the radionuclide. Radiances of controls were then compared across plates to check for bias (such as overestimation of radiance based upon bleed over from adjacent wells). Radioluminesence studies were additionally done to confirm effect of radionuclide decay from adjacent wells exciting other wells. Animals used for in vivo imaging were randomized for selection in imaging experiments.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
No formal blinding was done for these experiments
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
All IVIS ROIs were drawn in Living Image V4.5 and tabulated in Microsoft Excel and the mean and standard deviation plotted in Graphpad Prism V6 and V7. SPECT data was processed on a workstation running invivoscope and HISPEC. ROIs for SPECT images were drawn from DICOM images using Amide V 1.0.4. Only code written for this manuscript encompasses an addendum to the radionuclide tables in the MEDISO nanoSPECT to include X-rays energies based upon the element NP used.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
Nanoparticles used in this manuscript can be acquired commercially. only restriction on materials would be the end user's access to radionuclides.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
No antibodies or proteins were used in this manuscript 10 . Eukaryotic cell lines a. State the source of each eukaryotic cell line used. Figure 5a -d used the BT-474 cell line which was implanted orthotopically under the mammary pad of female nude mice. BT-474 cell lines were acquired from ATCC and frozen stocks authenticated to confirm adherence to STR profile.
b. Describe the method of cell line authentication used. Cell lines were not authenticated for the BT-474 cell line.
c. Report whether the cell lines were tested for mycoplasma contamination.
Cells were tested for mycoplasm contamination and determined to be negative.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used
